摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6-chloro-4-hydroxypyridin-2-yl)(phenyl)methanone | 1300040-33-8

中文名称
——
中文别名
——
英文名称
(6-chloro-4-hydroxypyridin-2-yl)(phenyl)methanone
英文别名
2-benzoyl-6-chloro-1H-pyridin-4-one
(6-chloro-4-hydroxypyridin-2-yl)(phenyl)methanone化学式
CAS
1300040-33-8
化学式
C12H8ClNO2
mdl
——
分子量
233.654
InChiKey
VXAAOIICMJZWIR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    46.2
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    (6-chloro-4-hydroxypyridin-2-yl)(phenyl)methanone溶剂黄146(-)-diisopinocamphenylborane chloride 作用下, 以 四氢呋喃 为溶剂, 反应 19.0h, 生成 (S)-4-hydroxy-6-(hydroxy(phenyl)methyl)pyridin-2(1H)-one
    参考文献:
    名称:
    SPF32629A and SPF32629B: Enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation
    摘要:
    We report herein an efficient enantioselective synthesis of SPF32629A and SPF32629B through one-pot enantioselective reduction and protecting-group-free regioselective O-acylation strategy. The absolute configuration of the enantiomerically pure isomers was established by Mosher ester analysis. The inhibitory potencies of the synthesized compounds were assayed in vitro against a panel of microorganisms and against A549 human lung adenocarcinoma cell line. Compounds 2, 11 and 12 displayed moderate to potent antibacterial activity against all the tested strains and compounds 7, 8, 2, 11 and 12 exhibited significant cytotoxicity in a dose-dependent manner with an IC50 values ranging from 2.92 to 4.14 mu g/ml and 8-11 mu M. (C) 2011 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2011.02.039
  • 作为产物:
    描述:
    (4-(benzyloxy)-6-chloropyridin-2-yl)(phenyl)methanone 在 溶剂黄146 作用下, 反应 6.0h, 以83%的产率得到(6-chloro-4-hydroxypyridin-2-yl)(phenyl)methanone
    参考文献:
    名称:
    SPF32629A and SPF32629B: Enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation
    摘要:
    We report herein an efficient enantioselective synthesis of SPF32629A and SPF32629B through one-pot enantioselective reduction and protecting-group-free regioselective O-acylation strategy. The absolute configuration of the enantiomerically pure isomers was established by Mosher ester analysis. The inhibitory potencies of the synthesized compounds were assayed in vitro against a panel of microorganisms and against A549 human lung adenocarcinoma cell line. Compounds 2, 11 and 12 displayed moderate to potent antibacterial activity against all the tested strains and compounds 7, 8, 2, 11 and 12 exhibited significant cytotoxicity in a dose-dependent manner with an IC50 values ranging from 2.92 to 4.14 mu g/ml and 8-11 mu M. (C) 2011 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2011.02.039
点击查看最新优质反应信息

文献信息

  • SPF32629A and SPF32629B: Enantioselective synthesis, determination of absolute configuration, cytotoxicity and antibacterial evaluation
    作者:Srinivasa Rao Vegi、Shanthaveerappa K. Boovanahalli、Balaram Patro、K. Mukkanti
    DOI:10.1016/j.ejmech.2011.02.039
    日期:2011.5
    We report herein an efficient enantioselective synthesis of SPF32629A and SPF32629B through one-pot enantioselective reduction and protecting-group-free regioselective O-acylation strategy. The absolute configuration of the enantiomerically pure isomers was established by Mosher ester analysis. The inhibitory potencies of the synthesized compounds were assayed in vitro against a panel of microorganisms and against A549 human lung adenocarcinoma cell line. Compounds 2, 11 and 12 displayed moderate to potent antibacterial activity against all the tested strains and compounds 7, 8, 2, 11 and 12 exhibited significant cytotoxicity in a dose-dependent manner with an IC50 values ranging from 2.92 to 4.14 mu g/ml and 8-11 mu M. (C) 2011 Elsevier Masson SAS. All rights reserved.
查看更多